1
|
d'Entremont MA, Couture ÉL, Connelly K, Walling A, Jolly SS, Valettas N, Tsang MB, Mampuya W, Poirier P, Huynh T. Management of the master endurance athlete with stable coronary artery disease. Can J Cardiol 2022; 38:1450-1453. [PMID: 35489669 DOI: 10.1016/j.cjca.2022.04.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 04/05/2022] [Accepted: 04/17/2022] [Indexed: 11/02/2022] Open
Abstract
Master endurance athletes are individuals > 35 years of age who either train for or participate in competitions. Considering the potential burden of coronary artery disease in this population, clinicians should be aware of the inherent dangers of exercise. A tailored approach with shared decision-making, balancing risks and benefits of exercise, is recommended to ensure safe exercise in these individuals.
Collapse
Affiliation(s)
| | - Étienne L Couture
- Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke (QC), Canada
| | - Kim Connelly
- Keenan Research Center, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (ON), Canada; Department of Physiology, University of Toronto, Toronto (ON), Canada; Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto (ON), Canada
| | - Ann Walling
- Sir Mortimer B. Davis Jewish General Hospital, Montreal (QC), Canada
| | - Sanjit S Jolly
- McGill Health University Center, Montreal (QC), Canada; Division of Cardiology, Department of Medicine, McMaster University, Hamilton Health Sciences, Hamilton (ON), Canada
| | - Nicholas Valettas
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton Health Sciences, Hamilton (ON), Canada
| | - Micheal B Tsang
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton Health Sciences, Hamilton (ON), Canada
| | - Warner Mampuya
- Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke (QC), Canada
| | - Paul Poirier
- Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec (QC), Canada
| | - Thao Huynh
- McGill Health University Center, Montreal (QC), Canada.
| |
Collapse
|
2
|
Siddiqi N, Shatat IF. Antihypertensive agents: a long way to safe drug prescribing in children. Pediatr Nephrol 2020; 35:2049-2065. [PMID: 31676933 PMCID: PMC7515858 DOI: 10.1007/s00467-019-04314-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 07/12/2019] [Accepted: 07/23/2019] [Indexed: 01/07/2023]
Abstract
Recently updated clinical guidelines have highlighted the gaps in our understanding and management of pediatric hypertension. With increased recognition and diagnosis of pediatric hypertension, the use of antihypertensive agents is also likely to increase. Drug selection to treat hypertension in the pediatric patient population remains challenging. This is primarily due to a lack of large, well-designed pediatric safety and efficacy trials, limited understanding of pharmacokinetics in children, and unknown risk of prolonged exposure to antihypertensive therapies. With newer legislation providing financial incentives for conducting clinical trials in children, along with publication of pediatric-focused guidelines, literature available for antihypertensive agents in pediatrics has increased over the last 20 years. The objective of this article is to review the literature for safety and efficacy of commonly prescribed antihypertensive agents in pediatrics. Thus far, the most data to support use in children was found for angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB). Several gaps were noted in the literature, particularly for beta blockers, vasodilators, and the long-term safety profile of antihypertensive agents in children. Further clinical trials are needed to guide safe and effective prescribing in the pediatric population.
Collapse
Affiliation(s)
- Nida Siddiqi
- Department of Pharmacy, Sidra Medicine, Doha, Qatar
| | - Ibrahim F Shatat
- Pediatric Nephrology and Hypertension, Sidra Medicine, HB. 7A. 106A, PO Box 26999, Doha, Qatar.
- Weill Cornell College of Medicine-Qatar, Ar-Rayyan, Qatar.
- Medical University of South Carolina, Charleston, SC, USA.
| |
Collapse
|
3
|
Abstract
Athletes of various skill levels commonly use many different types of medications, often at rates higher than the general population. Common medication classes used in athletes include analgesics such as nonsteroidal anti-inflammatory drugs and acetaminophen, inhalers for asthma and exercise-induced bronchoconstriction, antihypertensives, antibiotics, and insulin. Prescribers must be aware of the unique considerations for each of these medications when using them in patients participating in physical activity. The safety, efficacy, impact on athletic performance, and regulatory restrictions of the most common medications used in athletes are discussed in this article.
Collapse
Affiliation(s)
- Benjamin Ferry
- Trident/MUSC Family Medicine Residency Program, Department of Family Medicine, Medical University of South Carolina, 9228 Medical Plaza Drive, Charleston, SC 29406, USA
| | - Alexei DeCastro
- Department of Family Medicine, Medical University of South Carolina, College of Medicine, 9228 Medical Plaza Drive, Charleston, SC 29406, USA
| | - Scott Bragg
- Department of Family Medicine, College of Medicine, College of Pharmacy, Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina, 280 Calhoun Street MSC 140, Charleston, SC 29425, USA.
| |
Collapse
|
4
|
Abstract
Hypertension continues to be the most common cardiovascular disorder in the USA and worldwide. While generally considered a disorder of aging individuals, hypertension is more prevalent in athletes and the active population than is generally appreciated. The timely detection, diagnosis, and appropriate treatment of hypertension in athletes must focus on both adequately managing the disorder and ensuring safe participation in sport while not compromising exercise capacity. This publication focuses on appropriately diagnosing hypertension, treating hypertension in the athletic population, and suggesting follow-up and participation guidelines for athletes.
Collapse
Affiliation(s)
- Kevin T Schleich
- Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.,Department of Family Medicine, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA
| | - M Kyle Smoot
- Department of Orthopaedic Surgery & Sports Medicine, University of Kentucky, Lexington, KY, USA
| | - Michael E Ernst
- Department of Family Medicine, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA. .,Department of Pharmacy Practice and Science, College of Pharmacy, The University of Iowa, Iowa City, IA, USA.
| |
Collapse
|
5
|
Terpak K, Guthrie S, Erickson S. Statin use and self-reported swimming performance in US masters swimmers. J Sports Sci 2014; 33:286-92. [DOI: 10.1080/02640414.2014.942688] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
6
|
Wexler R, Pleister A, Raman SV, Borchers JR. Therapeutic lifestyle changes for cardiovascular disease. PHYSICIAN SPORTSMED 2012; 40:109-15. [PMID: 22508257 DOI: 10.3810/psm.2012.02.1957] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Cardiovascular disease, including hypertension, coronary artery disease, and heart failure, is common in the general US population. The mainstay of treatment for this cohort is implementing therapeutic lifestyle changes (TLCs). Therapeutic lifestyle changes include a reduced-sodium diet, the Dietary Approaches to Stop Hypertension (DASH) diet, weight loss, moderation of alcohol consumption, and increased aerobic exercise. It is important to emphasize that exercise should be recommended to all patients, even for those who historically were told not do so, such as those with heart failure. When prescribing harmacotherapy, physical activity should be taken into account. Athletes competing at the top level warrant adherence to the restrictions of the World Anti-Doping Agency.
Collapse
Affiliation(s)
- Randell Wexler
- Department of Family Medicine, The Ohio State University, Columbus, OH 43201, USA.
| | | | | | | |
Collapse
|